logo-loader
AEterna Zentaris Inc.

Aeterna Zentaris sees revenue boost in 3Q, ends the quarter debt-free

Its product Macimorelin is used in the diagnosis of adult growth hormone deficiency

Scientist sitting and looking into a microscope
Aeterna Zentaris specializes in oncology and endocrine therapy

Aeterna Zentaris Inc (NASDAQ:AEZS) reported a narrower loss in this year’s third-quarter results, more than doubling its revenue.

The biotech reported a net loss of $0.15 per share on revenue of $663,000 compared with a net loss of $0.61 on revenue of $241,000 in the previous year’s third quarter.

The South Carolina-based company ended the quarter debt-free with $16.8 million in cash on hand.

Shares slipped nearly 7% to $2.21 in Wednesday morning trading.

READ: Nemaura develops predictive algorithms, alarm functionality for its sugarBEAT glucose monitor

Aeterna Zentaris entered into a licensing agreement with a subsidiary of Strongbridge Ireland Ltd back in January 2018 to develop Macrilen, also known as macimorelin, in the US and Canada.

Macrilen is used in the diagnosis of adult growth hormone deficiency, a rare endocrine disorder.

In early November, Strongbridge BioPharma signed an agreement with Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) to hand over the rights to Macrilen in the US and Canada.

The company has been advancing its plans to move into Europe, submitting Macrilen to the European Medicines Agency’s Committee for Medicinal Products for Human Use.

The CHMP takes part in authorizing the use of medicines in the European Union.

"We are very pleased with the progress we are making in the European Union and of the Company’s Day-181 CHMP submission of macimorelin to the European Medicines Agency last month and anticipate a decision from the European Commission in the first quarter of 2019,” said CEO Michael V. Ward in the company’s press release.

The drug development company specializes in oncology and endocrine therapy.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

Quick facts: AEterna Zentaris Inc.

Price: $1.70

Market: TSX
Market Cap: $28.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Alchemist sees big market in China for medical cannabis sales

Alchemist (CSE: AMS) CEO Paul Mann and Vice President of Business Development, Asia Pacific Johnson Lee joined Steve Darling from Proactive Vancouver to discuss Alchemist looking for opportunities for cannabis in the emerging cannabis market.  Mann and Lee talk about what the industry...

2 days, 4 hours ago

2 min read